This study also described that the ORRs with ICIs were 25% and 33% in groups A and B, respectively, and the median PFS rates with ICIs were 3.7 and 4.1 months in groups A and B, respectively, indicating that ICIs may have favorable anti-tumor activity for both BRAF V600E and BRAF non-V600E mutant NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.